Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

GALT Insider Trading

GALECTIN THERAPEUTICS INC | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at GALECTIN THERAPEUTICS INC provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2016-04-22 02:35 2016-04-19 10X Fund, L.P. 10% owner SELL $1.67 44,312 $74,138 3,260,697 -1.3%
2016-04-22 00:06 2016-04-19 CZIRR JAMES C Director SELL $1.67 44,312 $74,138 3,260,697 -1.3%
2016-01-08 01:31 2016-01-05 Greenberg Arthur Director BUY $1.72 1,666 $2,866 109,445 +1.5%
2015-12-02 18:34 2015-11-30 AMELIO GILBERT F Director SELL $2.10 100 $210 119,961 -0.1%
2015-08-13 00:02 2015-08-12 TRABER PETER G Director, Officer - President & CEO BUY $2.00 2,000 $4,000 107,333 +1.9%
2015-06-03 00:35 2015-06-01 FREEMAN KEVIN D Director BUY $2.70 2,083 $5,624 2,083 +100.0%
2015-06-01 23:39 2015-06-01 TRABER PETER G Officer - President & CEO BUY $2.53 4,000 $10,120 105,333 +3.9%
2014-12-18 00:36 2014-12-15 AMELIO GILBERT F Director SELL $3.69 110 $406 91,974 -0.1%
2014-08-20 18:30 2014-08-19 Greenberg Arthur Director BUY $4.56 1,000 $4,560 96,667 +1.0%
2014-08-18 17:11 2014-08-15 FREEMAN KEVIN D Director BUY $4.70 1,000 $4,700 3,917 +34.3%
2014-08-15 16:05 2014-08-14 CALLICUTT JACK W Officer - Chief Financial Officer BUY $4.55 1,000 $4,545 1,260 +384.6%
2014-08-15 16:04 2014-08-14 TRABER PETER G Director, Officer - President and CEO BUY $4.46 4,000 $17,838 101,333 +4.1%
2014-08-14 17:37 2014-08-13 TRABER PETER G Director, Officer - President and CEO BUY $4.42 1,000 $4,416 97,333 +1.0%
2014-01-15 01:07 2014-01-10 Martin Rod D Director SELL $14.84 100,000 $1,484,320 9,357,422 -1.1%
2014-01-15 01:07 2014-01-10 CZIRR JAMES C Director, Officer - Executive Chairman SELL $14.84 100,000 $1,484,320 9,357,422 -1.1%
2014-01-15 01:06 2014-01-10 10X Fund, L.P. 10% owner SELL $14.84 100,000 $1,484,320 9,357,422 -1.1%
2014-01-03 01:31 2014-01-02 MAULDIN JOHN F Director BUY $8.01 618 $4,950 18,074 +3.5%
2013-12-11 01:05 2013-12-09 TRABER PETER G Director, Officer - President and CEO BUY $8.90 500 $4,450 96,333 +0.5%
2013-12-06 02:41 2013-12-05 TRABER PETER G Director, Officer - President and CEO BUY $9.00 500 $4,500 95,833 +0.5%
2013-12-05 01:29 2013-12-04 Rubin Marc Director BUY $8.69 3,000 $26,070 6,334 +90.0%
2013-12-04 01:04 2013-12-02 MAULDIN JOHN F Director BUY $8.20 609 $4,992 17,456 +3.6%
2013-11-20 00:43 2013-11-19 CALLICUTT JACK W Officer - Chief Financial Officer BUY $6.25 260 $1,625 260 +100.0%
2013-11-20 00:31 2013-11-19 Greenberg Arthur Director BUY $6.55 2,000 $13,102 95,667 +2.1%
2013-11-19 21:20 2013-11-19 TRABER PETER G Director, Officer - President and CEO BUY $5.53 1,000 $5,530 95,333 +1.1%
2013-11-19 21:07 2013-11-18 FREEMAN KEVIN D Director BUY $6.08 1,000 $6,078 2,917 +52.2%
2013-11-19 17:07 2013-11-18 Shlevin Harold H. Officer - Chief Operating Officer BUY $6.63 500 $3,315 53,914 +0.9%
2013-11-19 17:05 2013-11-18 TRABER PETER G Director, Officer - President and CEO BUY $5.80 1,000 $5,799 511,000 +0.2%
2013-11-18 16:54 2013-11-15 CZIRR JAMES C Director, Officer - Executive Chairman BUY $6.90 1,000 $6,897 844,450 +0.1%
2013-11-05 01:14 2013-11-01 MAULDIN JOHN F Director BUY $10.43 478 $4,985 16,847 +2.9%
2013-10-10 00:12 2013-10-07 Martin Rod D Director SELL $11.85 112,000 $1,327,424 8,957,422 -1.2%
2013-10-10 00:11 2013-10-07 CZIRR JAMES C Director, Officer - Executive Chairman SELL $11.85 112,000 $1,327,424 8,957,422 -1.2%
2013-10-10 00:10 2013-10-07 10X Fund, L.P. 10% owner SELL $11.85 112,000 $1,327,424 8,957,422 -1.2%
2013-10-04 00:18 2013-10-01 MAULDIN JOHN F Director BUY $9.97 501 $4,992 16,369 +3.2%
2013-09-07 00:03 2013-09-04 MAULDIN JOHN F Director BUY $7.38 676 $4,988 15,868 +4.4%
2013-08-07 00:20 2013-08-05 MAULDIN JOHN F Director BUY $5.94 840 $4,988 15,192 +5.9%
2013-07-09 00:06 2013-07-03 MAULDIN JOHN F Director BUY $4.23 876 $3,709 14,352 +6.5%
2013-07-03 19:27 2013-07-01 MAULDIN JOHN F Director BUY $4.24 300 $1,273 13,476 +2.3%
2013-06-05 00:59 2013-06-03 MAULDIN JOHN F Director BUY $4.21 1,176 $4,954 13,176 +9.8%
2013-05-30 18:19 2013-05-28 FREEMAN KEVIN D Director BUY $4.21 1,000 $4,212 6,500 +18.2%
2012-10-16 00:14 2012-10-12 TRABER PETER G Director, Officer - President and CEO BUY $2.11 2,500 $5,287 510,000 +0.5%
2012-10-11 00:13 2012-10-09 TRABER PETER G Director, Officer - President and CEO BUY $2.00 2,500 $5,000 507,500 +0.5%
2012-10-10 00:20 2012-10-08 TRABER PETER G Director, Officer - President and CEO BUY $2.07 5,000 $10,350 505,000 +1.0%
2012-07-20 22:23 2012-07-18 Greenberg Arthur Director BUY $1.84 5,000 $9,200 94,667 +5.6%
2012-06-21 23:12 2012-06-20 AMELIO GILBERT F Director BUY $2.10 7,500 $15,750 92,084 +8.9%
2012-05-25 23:54 2012-05-25 Martin Rod D Director BUY $2.44 5,000 $12,200 91,488 +5.8%
2012-05-25 21:13 2012-05-24 MCGAULEY THOMAS Officer - Chief Financial Officer BUY $2.35 10,000 $23,500 10,000 +100.0%
2012-05-18 22:39 2012-05-17 CZIRR JAMES C Director, Officer - Executive Chairman BUY $2.25 10,000 $22,500 843,450 +1.2%
2012-04-27 01:23 2012-04-24 MAULDIN JOHN F Director BUY $2.97 4,947 $14,698 4,947 +100.0%
2012-04-27 01:08 2012-04-25 PRESSLER HERMAN PAUL Director BUY $3.10 5,000 $15,515 9,500 +111.1%
2012-04-19 01:28 2012-04-17 Greenberg Arthur Director BUY $2.84 3,000 $8,520 89,667 +3.5%
SHOW ENTRIES

How to Interpret $GALT Trades

Not every insider transaction in GALECTIN THERAPEUTICS INC is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $GALT shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for GALT

Insider activity data for GALECTIN THERAPEUTICS INC is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $GALT, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.